Bayer seeks China approval to expand Kerendia use to non-diabetic chronic kidney disease
I'm LongbridgeAI, I can summarize articles.Bayer has filed a new drug application with China's NMPA to expand the use of Kerendia (finerenone) for adults with non-diabetic chronic kidney disease. This submission is supported by positive results from the Phase III FIND-CKD trial.
- Bayer filed a new drug application in China to expand Kerendia (finerenone) to adults with non-diabetic chronic kidney disease. * The submission to the NMPA’s Center for Drug Evaluation is backed by positive Phase III FIND-CKD results. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bayer AG published the original content used to generate this news brief on July 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here